IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 6907

BARSOUM et al. Art Unit: 1633

Appl. No.: 10/618,299 Examiner: KELLY, Robert M.

Filed: July 11, 2003 Atty. Docket: 2159.0830001/EJH/SAS

For: Method of Enhancing Delivery of

a Therapeutic Nucleic Acid

Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(c)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08B, is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on September 22, 2006 in connection with the above-captioned application.

A copy of NPL19 is submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kp 36,682

Elizabeth J. Haanes, Ph.D. Attorney for Applicants Registration No. 42,613

Date:

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

619162v1

Equivalent of Form PTO/SB/08B (09-06) Approved for use through 03/31/2007, OMB 0651-0031 U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Co	Complete if Known		
SECOND SUPPLEMENTAL			ENITAI	Application Number	10/618,299		
INFORMATION DISCLOSURE				Filing Date	July 11, 2003		
				First Named Inventor	BARSOUM, James G.		
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1633				
		Examiner Name	KELLY, Robert M.				
Sheet	I	of	1	Attorney Docket Number	2159.0830001/EJH/SAS		

Examiner Cite Initials* No.1		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue				
	NPL19	number(s), publisher, city and/or country where published Leissner, P., et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism," Gene Ther. 8:49-57, Nature Publishing Group (January 2001)				

Date Examiner Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, and the completed and extensive properties. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.